Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Malignant Lymphoma

  Free Subscription


Articles published in Bone Marrow Transplant

Retrieve available abstracts of 75 articles:
HTML format



Single Articles


    June 2022
  1. MEISSNER J, Schmitt M, Andrulis M, Schweizer L, et al
    Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation.
    Bone Marrow Transplant. 2022 Jun 9. pii: 10.1038/s41409-022-01734.
    PubMed    


  2. YANG JC, Scordo M, Chau KW, Sauter CS, et al
    Highly favorable outcomes with salvage radiation therapy and autologous hematopoietic cell transplantation in relapsed and refractory DLBCL patients with minimal to no response to salvage chemotherapy.
    Bone Marrow Transplant. 2022;57:1038-1041.
    PubMed    


    May 2022
  3. FERNANDEZ-SOJO J, Cid J, Azqueta C, Valdivia E, et al
    Post thawing viable CD34+ Cells dose is a better predictor of clinical outcome in lymphoma patients undergoing autologous stem cell transplantation.
    Bone Marrow Transplant. 2022 May 25. pii: 10.1038/s41409-022-01722.
    PubMed    


  4. ANGELOV D, Dillon J, Mellerick L, Pender E, et al
    Allogeneic transplantation in Cutaneous T-cell Lymphoma: improved outcomes associated with early transplantation and acute graft versus host disease.
    Bone Marrow Transplant. 2022 May 20. pii: 10.1038/s41409-022-01713.
    PubMed    


  5. FRIETSCH JJ, Miethke J, Linke P, Crodel CC, et al
    Treosulfan plus fludarabine versus TEAM as conditioning treatment before autologous stem cell transplantation for B-cell Non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 May 10. pii: 10.1038/s41409-022-01701.
    PubMed     Abstract available


    April 2022
  6. SCHENONE L, Houillier C, Tanguy ML, Choquet S, et al
    Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life-experience of the French Network.
    Bone Marrow Transplant. 2022 Apr 14. pii: 10.1038/s41409-022-01648.
    PubMed     Abstract available


  7. LIU H, Liu W, Li R, Jiao Y, et al
    A gemcitabine-based regimen followed by autologous stem cell transplantation show high efficacy and well tolerance in malignant lymphoma.
    Bone Marrow Transplant. 2022 Apr 7. pii: 10.1038/s41409-022-01655.
    PubMed    


  8. HEINI AD, Bacher U, Kronig MN, Wiedemann G, et al
    Chimeric antigen receptor T-cell therapy for relapsed mantle cell lymphoma: real-world experience from a single tertiary care center.
    Bone Marrow Transplant. 2022 Apr 5. pii: 10.1038/s41409-022-01658.
    PubMed    


    March 2022
  9. GALLI E, Sora F, Hohaus S, Bellesi S, et al
    Autologous stem cell transplantation as bridging therapy followed by CD19 CAR-T cells in relapsed-refractory large B cell lymphoma.
    Bone Marrow Transplant. 2022 Mar 8. pii: 10.1038/s41409-022-01632.
    PubMed    


  10. HERNANDEZ-BOLUDA JC, Pereira A, Zinger N, Gras L, et al
    Allogeneic hematopoietic cell transplantation in patients with myeloid/lymphoid neoplasm with FGFR1-rearrangement: a study of the Chronic Malignancies Working Party of EBMT.
    Bone Marrow Transplant. 2022;57:416-422.
    PubMed     Abstract available


    February 2022
  11. YOON SE, Jo H, Kang ES, Cho D, et al
    Role of upfront autologous stem cell transplantation in patients newly diagnosed with primary CNS lymphoma treated with R-MVP: real-world data from a retrospective single-center analysis.
    Bone Marrow Transplant. 2022 Feb 16. pii: 10.1038/s41409-022-01605.
    PubMed     Abstract available


  12. COSTES-TERTRAIS D, Hueso T, Gastinne T, Thieblemont C, et al
    Bendamustine-EAM versus R-BEAM after high-dose cytarabine-based induction in newly diagnosed patients with mantle cell lymphoma, a LYSA retrospective study.
    Bone Marrow Transplant. 2022 Feb 11. pii: 10.1038/s41409-022-01596.
    PubMed     Abstract available


  13. HUSBY S, Jorgensen GO, Favero F, Jespersen JS, et al
    Level of unique T cell clonotypes is associated with clonal hematopoiesis and survival in patients with lymphoma undergoing ASCT.
    Bone Marrow Transplant. 2022 Feb 5. pii: 10.1038/s41409-022-01580.
    PubMed    


  14. FRIEND BD, Muhsen IN, Patel S, Hill LC, et al
    Rituximab as adjunctive therapy to BEAM conditioning for autologous stem cell transplantation in Hodgkin lymphoma.
    Bone Marrow Transplant. 2022 Feb 1. pii: 10.1038/s41409-022-01599.
    PubMed     Abstract available


  15. WALLADBEGI J, Henriksson R, Tavelin B, Svanberg A, et al
    Efficacy of a novel device for cryoprevention of oral mucositis: a randomized, blinded, multicenter, parallel group, phase 3 trial.
    Bone Marrow Transplant. 2022;57:191-197.
    PubMed     Abstract available


    January 2022
  16. LIEVIN R, Di Blasi R, Morin F, Galli E, et al
    Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed/refractory B-cell lymphoma.
    Bone Marrow Transplant. 2022 Jan 30. pii: 10.1038/s41409-021-01526.
    PubMed     Abstract available


    November 2021
  17. LEAL CTS, Costa LJM, Pereira J, Duarte FB, et al
    Maximum-tolerated dose of lomustine used in combination with etoposide and cyclophosphamide in conditioning regimen for hematopoietic stem cell transplantation in lymphoma patients.
    Bone Marrow Transplant. 2021 Nov 29. pii: 10.1038/s41409-021-01531.
    PubMed    


    October 2021
  18. DWORKIN ML, Jiang AL, Von Eyben R, Spinner MA, et al
    Outcomes of adults with lymphoma treated with nonmyeloablative TLI-ATG and radiation boost to high risk or residual disease before allogeneic hematopoietic cell transplant.
    Bone Marrow Transplant. 2021 Oct 20. pii: 10.1038/s41409-021-01495.
    PubMed     Abstract available


  19. SALVINI M, Maggi F, Damonte C, Mortara L, et al
    Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation.
    Bone Marrow Transplant. 2021 Oct 11. pii: 10.1038/s41409-021-01487.
    PubMed    


  20. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Correction: Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2021 Oct 7. pii: 10.1038/s41409-021-01490.
    PubMed    


  21. MILLARD T, Sammour F, Anthias C, Easdale S, et al
    Can pre-transplant 18F-choline positron emission tomography predict relapse following autologous stem cell transplantation in primary central nervous system lymphoma?
    Bone Marrow Transplant. 2021 Oct 5. pii: 10.1038/s41409-021-01484.
    PubMed    


    August 2021
  22. INOUE Y, Nakano N, Fuji S, Eto T, et al
    Impact of conditioning intensity and regimen on transplant outcomes in patients with adult T-cell leukemia-lymphoma.
    Bone Marrow Transplant. 2021 Aug 31. pii: 10.1038/s41409-021-01445.
    PubMed     Abstract available


  23. MUNSHI PN, Hamadani M, Kumar A, Dreger P, et al
    ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma.
    Bone Marrow Transplant. 2021 Aug 20. pii: 10.1038/s41409-021-01288.
    PubMed     Abstract available


  24. TAMAI H, Tajika K, Nakayama K, Arai A, et al
    Treatment of relapsed aggressive adult T-cell leukemia/lymphoma after allogeneic hematopoietic stem cell transplantation with mogamulizumab followed by lenalidomide.
    Bone Marrow Transplant. 2021 Aug 12. pii: 10.1038/s41409-021-01432.
    PubMed    


  25. CORNILLON J, Daguenet E, Tournilhac O, Blaise D, et al
    Allogeneic hematopoietic stem cell transplantation from unmanipulated haploidentical donor and unrelated cord blood for T-cell lymphoma: a retrospective study from the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire.
    Bone Marrow Transplant. 2021 Aug 6. pii: 10.1038/s41409-021-01426.
    PubMed     Abstract available


    July 2021
  26. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease.
    Bone Marrow Transplant. 2021 Jul 20. pii: 10.1038/s41409-021-01418.
    PubMed    


  27. LOWENBERG B, Kersten MJ, Gale RP, van Oers M, et al
    Professor Anton Hagenbeek 1948-2021: Father of MRD and lymphoma expert.
    Bone Marrow Transplant. 2021 Jul 19. pii: 10.1038/s41409-021-01375.
    PubMed    


  28. CORTELAZZO S, Mian M, Evangelista A, Devizzi L, et al
    Upfront intensive chemo-immunotherapy with autograft in 199 adult mantle cell lymphoma patients: prolonged survival and cure potentiality at long term.
    Bone Marrow Transplant. 2021 Jul 7. pii: 10.1038/s41409-021-01391.
    PubMed    


    June 2021
  29. GEVA M, Pryce A, Shouval R, Fein JA, et al
    High lactate dehydrogenase at time of admission for allogeneic hematopoietic transplantation associates to poor survival in acute myeloid leukemia and non-Hodgkin lymphoma.
    Bone Marrow Transplant. 2021 Jun 29. pii: 10.1038/s41409-021-01377.
    PubMed     Abstract available


  30. BONIFAZI F, Defrancesco I, Olivieri J, Barbato F, et al
    Low doses ATLG as GvHD prophylaxis in allogeneic hematopoietic stem cell transplantation for lymphomas.
    Bone Marrow Transplant. 2021 Jun 9. pii: 10.1038/s41409-021-01359.
    PubMed    


    May 2021
  31. VIJENTHIRA A, Kuruvilla J, Prica A
    Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
    Bone Marrow Transplant. 2021 May 13. pii: 10.1038/s41409-021-01327.
    PubMed     Abstract available


  32. DERENZINI E, Tabanelli V, Sammassimo S, Mazzara S, et al
    Pre-existing immune checkpoints activation predicts relapse after allogeneic stem cell transplantation in lymphoma.
    Bone Marrow Transplant. 2021 May 7. pii: 10.1038/s41409-021-01320.
    PubMed    


    April 2021
  33. TOYODA K, Yasunaga JI, Choi I, Suehiro Y, et al
    The HTLV-1 proviral status is a potential prognostic biomarker for adult T-cell leukemia-lymphoma treated with allogeneic stem cell transplantation.
    Bone Marrow Transplant. 2021 Apr 29. pii: 10.1038/s41409-021-01311.
    PubMed    


  34. EYRE TA, Caillard S, Finel H, Boumendil A, et al
    Autologous stem cell transplantation for post-transplant lymphoproliferative disorders after solid organ transplantation: a retrospective analysis from the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2021 Apr 16. pii: 10.1038/s41409-021-01270.
    PubMed     Abstract available


  35. SHAPIRO LC, Mustafa J, Lombardo A, Khatun F, et al
    Safety of axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma in an elderly intercity population.
    Bone Marrow Transplant. 2021 Apr 12. pii: 10.1038/s41409-021-01280.
    PubMed    


    March 2021
  36. BENTO L, Gutierrez A, Novelli S, Montoro J, et al
    Allogeneic stem cell transplantation as a curative option in relapse/refractory diffuse large B cell lymphoma: Spanish multicenter GETH/GELTAMO study.
    Bone Marrow Transplant. 2021 Mar 25. pii: 10.1038/s41409-021-01264.
    PubMed     Abstract available


  37. IMOTO H, Yoshioka S, Hiramoto N, Morita-Fujita M, et al
    Haploidentical peripheral blood stem cell transplantation with posttransplant cyclophosphamide for systemic Epstein-Barr virus-positive T-cell lymphoma of childhood.
    Bone Marrow Transplant. 2021 Mar 10. pii: 10.1038/s41409-021-01263.
    PubMed    


  38. TESSOULIN B, Chiron D, Thieblemont C, Oberic L, et al
    Oxaliplatin before autologous transplantation in combination with high-dose cytarabine and rituximab provides longer disease control than cisplatin or carboplatin in patients with mantle-cell lymphoma: results from the LyMA prospective trial.
    Bone Marrow Transplant. 2021 Mar 3. pii: 10.1038/s41409-020-01198.
    PubMed     Abstract available


  39. PYTLIK R, Vackova B, Konirova E, Trnkova M, et al
    Long-term outcomes of older patients with relapsed/refractory NHL referred to ASCT.
    Bone Marrow Transplant. 2021;56:709-712.
    PubMed    


    February 2021
  40. PRINCE HM, Abeyakoon C
    Allogeneic haematopoietic stem cell transplantation for advanced stage mycosis fungoides and Sezary syndrome: never-late, never-never?
    Bone Marrow Transplant. 2021 Feb 1. pii: 10.1038/s41409-020-01150.
    PubMed    


    January 2021
  41. SAKURAI M, Mori T, Kato K, Kanaya M, et al
    Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation.
    Bone Marrow Transplant. 2021 Jan 29. pii: 10.1038/s41409-020-01192.
    PubMed    


  42. PETTENGELL R, Uddin R, Boumendil A, Johnson R, et al
    Durable benefit of rituximab maintenance post-autograft in patients with relapsed follicular lymphoma: 12-year follow-up of the EBMT lymphoma working party Lym1 trial.
    Bone Marrow Transplant. 2021 Jan 15. pii: 10.1038/s41409-020-01182.
    PubMed     Abstract available


  43. DOMINGO-DOMENECH E, Duarte RF, Boumedil A, Onida F, et al
    Allogeneic hematopoietic stem cell transplantation for advanced mycosis fungoides and Sezary syndrome. An updated experience of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation.
    Bone Marrow Transplant. 2021 Jan 8. pii: 10.1038/s41409-020-01197.
    PubMed     Abstract available


    December 2020
  44. MONTORO J, Chorao P, Bento L, Cabrero M, et al
    Risk factors and outcomes of follicular lymphoma after allogeneic hematopoietic stem cell transplantation using HLA-matched sibling, unrelated, and haploidentical-related donors.
    Bone Marrow Transplant. 2020 Dec 12. pii: 10.1038/s41409-020-01161.
    PubMed    


  45. SONG GY, Yoon DH, Suh C, Moon JH, et al
    Open-label, single arm, multicenter phase II study of VIDL induction chemotherapy followed by upfront autologous stem cell transplantation in patients with advanced stage extranodal NK/T-cell lymphoma.
    Bone Marrow Transplant. 2020 Dec 4. pii: 10.1038/s41409-020-01160.
    PubMed     Abstract available


  46. DANYLESKO I, Shouval R, Shem-Tov N, Yerushalmi R, et al
    Immune imitation of tumor progression after anti-CD19 chimeric antigen receptor T cells treatment in aggressive B-cell lymphoma.
    Bone Marrow Transplant. 2020 Dec 3. pii: 10.1038/s41409-020-01156.
    PubMed     Abstract available


    November 2020
  47. CASTAGNA L, Pagliardini T, Bramanti S, Schiano de Colella JM, et al
    Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome.
    Bone Marrow Transplant. 2020 Nov 15. pii: 10.1038/s41409-020-01133.
    PubMed     Abstract available


  48. GHAFOURI S, Timmerman J, Larson S, Mead MD, et al
    Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?
    Bone Marrow Transplant. 2020 Nov 10. pii: 10.1038/s41409-020-01099.
    PubMed    


  49. BERSVENDSEN HS, Haugnes HS, Dahl AA, Fagerli UM, et al
    Sexual dysfunction is prevalent in female lymphoma survivors after autologous stem-cell transplantation and is associated with younger age, chronic fatigue, and mental distress.
    Bone Marrow Transplant. 2020 Nov 3. pii: 10.1038/s41409-020-01098.
    PubMed     Abstract available


    October 2020
  50. BENTO L, Boumendil A, Finel H, Khvedelidze I, et al
    Tandem autologous-reduced intensity allogeneic stem cell transplantation in high-risk relapsed Hodgkin lymphoma: a retrospective study of the Lymphoma Working Party-EBMT.
    Bone Marrow Transplant. 2020 Oct 12. pii: 10.1038/s41409-020-01075.
    PubMed     Abstract available


    September 2020
  51. KELSEY P, Pearce R, Perry J, Kirkland K, et al
    Substituting carmustine for lomustine is safe and effective in the treatment of relapsed or refractory Lymphoma-a retrospective study from the BSBMT (BEAM versus LEAM).
    Bone Marrow Transplant. 2020 Sep 29. pii: 10.1038/s41409-020-01071.
    PubMed    


    August 2020
  52. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    Correction: GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Aug 25. pii: 10.1038/s41409-020-01037.
    PubMed     Abstract available


  53. BADAR T, Johnson BD, Hamadani M
    Delayed neurotoxicity after axicabtagene ciloleucel therapy in relapsed refractory diffuse large B-cell lymphoma.
    Bone Marrow Transplant. 2020 Aug 11. pii: 10.1038/s41409-020-01029.
    PubMed    


  54. ALLRED J, Bharucha K, Ozutemiz C, He F, et al
    Chimeric antigen receptor T-cell therapy for HIV-associated diffuse large B-cell lymphoma: case report and management recommendations.
    Bone Marrow Transplant. 2020 Aug 6. pii: 10.1038/s41409-020-01018.
    PubMed    


    July 2020
  55. GALLI E, Allain V, Di Blasi R, Bernard S, et al
    G-CSF does not worsen toxicities and efficacy of CAR-T cells in refractory/relapsed B-cell lymphoma.
    Bone Marrow Transplant. 2020 Jul 27. pii: 10.1038/s41409-020-01006.
    PubMed    


  56. MURANUSHI H, Shindo T, Hishizawa M, Tokunaga M, et al
    GVHD-free, relapse-free survival provides novel clues for optimizing allogeneic-HSCT for adult T-cell leukemia/lymphoma.
    Bone Marrow Transplant. 2020 Jul 14. pii: 10.1038/s41409-020-00996.
    PubMed     Abstract available


  57. CIUREA SO, Kongtim P, Srour S, Saini N, et al
    Can we cure refractory Hodgkin's lymphoma with transplantation?
    Bone Marrow Transplant. 2020 Jul 7. pii: 10.1038/s41409-020-0989.
    PubMed    


    June 2020
  58. SELBERG L, Stadtherr P, Dietrich S, Tran TH, et al
    The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis.
    Bone Marrow Transplant. 2020 Jun 18. pii: 10.1038/s41409-020-0976.
    PubMed     Abstract available


  59. YANG L, Tan Y, Shi J, Zhao Y, et al
    Correction: Allogeneic hematopoietic stem cell transplantation should be in preference to conventional chemotherapy as post-remission treatment for adults with lymphoblastic lymphoma.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0962.
    PubMed     Abstract available


  60. MERLI M, Luminari S, Farina L, Cocito F, et al
    Stem cell mobilization after bendamustine in indolent lymphomas: a multicenter study on behalf of the Fondazione Italiana Linfomi.
    Bone Marrow Transplant. 2020 Jun 15. pii: 10.1038/s41409-020-0967.
    PubMed    


    May 2020
  61. SELLNER L, Schetelig J, Koster L, Choi G, et al
    Idelalisib exposure before allogeneic stem cell transplantation in patients with follicular lymphoma: an EBMT survey.
    Bone Marrow Transplant. 2020 May 22. pii: 10.1038/s41409-020-0946.
    PubMed    


  62. SUREDA A, Genadieva Stavrik S, Boumendil A, Finel H, et al
    Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
    Bone Marrow Transplant. 2020 May 15. pii: 10.1038/s41409-020-0929.
    PubMed     Abstract available


  63. LIN RJ, Ho C, Devlin SM, Ruiz JD, et al
    Impact of allogeneic hematopoietic cell transplantation on immune evasive mechanisms in relapsed refractory large B-cell lymphoma.
    Bone Marrow Transplant. 2020 May 13. pii: 10.1038/s41409-020-0942.
    PubMed    


  64. DAMLAJ M, Abuelgasim KA, Alhejazi A, Alahmari B, et al
    Brentuximab vedotin containing salvage followed by consolidation post autologous hematopoietic stem cell transplantation in high risk relapsed refractory classical Hodgkin lymphoma.
    Bone Marrow Transplant. 2020 May 13. pii: 10.1038/s41409-020-0935.
    PubMed    


  65. ONISHI A, Inamoto Y, Tajima K, Yamaguchi J, et al
    Detrimental effects of pretransplant cisplatin-based chemotherapy on renal function after allogeneic hematopoietic cell transplantation for lymphoma.
    Bone Marrow Transplant. 2020 May 4. pii: 10.1038/s41409-020-0917.
    PubMed    


    April 2020
  66. DI RENZO N, Musso M, Scime R, Cupri A, et al
    Efficacy and safety of multiple doses of NEPA without dexamethasone in preventing nausea and vomiting induced by multiple-day and high-dose chemotherapy in patients with non-Hodgkin's lymphoma undergoing autologous hematopoietic stem cell transplantat
    Bone Marrow Transplant. 2020 Apr 28. pii: 10.1038/s41409-020-0909.
    PubMed     Abstract available


  67. MOHTY M, Dulery R, Gauthier J, Malard F, et al
    CAR T-cell therapy for the management of refractory/relapsed high-grade B-cell lymphoma: a practical overview.
    Bone Marrow Transplant. 2020 Apr 18. pii: 10.1038/s41409-020-0892.
    PubMed     Abstract available


  68. JO JC, Kim JS, Lee JH, Lee JH, et al
    Busulfan, etoposide, cytarabine, and melphalan (BuEAM) as a conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin lymphoma (NHL).
    Bone Marrow Transplant. 2020 Apr 17. pii: 10.1038/s41409-020-0908.
    PubMed    


  69. TALLEUR AC, Flerlage JE, Shook DR, Chilsen AM, et al
    Autologous hematopoietic cell transplantation for the treatment of relapsed/refractory pediatric, adolescent, and young adult Hodgkin lymphoma: a single institutional experience.
    Bone Marrow Transplant. 2020 Apr 9. pii: 10.1038/s41409-020-0879.
    PubMed     Abstract available


    February 2019
  70. FARNAULT L, Venton G, Pourroy B, Jourde-Chiche N, et al
    Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0467.
    PubMed    


  71. SINGER S, Sharma N, Dean R, Zhao Q, et al
    BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas.
    Bone Marrow Transplant. 2019 Feb 4. pii: 10.1038/s41409-019-0463.
    PubMed     Abstract available


    January 2019
  72. ABADIR E, Bryant C, Larsen S, Clark GJ, et al
    Targeting the niche: depleting haemopoietic stem cells with targeted therapy.
    Bone Marrow Transplant. 2019 Jan 21. pii: 10.1038/s41409-019-0445.
    PubMed     Abstract available


    October 2018
  73. KALOYANNIDIS P, Shaibani EA, Apostolidis I, Kanfar S, et al
    Combination of bortezomib plus ruxolitinib in steroid-refractory chronic graft-versus-host disease.
    Bone Marrow Transplant. 2018 Oct 18. pii: 10.1038/s41409-018-0362.
    PubMed    


  74. DE LA HOZ A, Foolad F, Gallegos C, Kornblau S, et al
    Nivolumab-induced encephalitis post allogeneic stem cell transplant in a patient with Hodgkin's disease.
    Bone Marrow Transplant. 2018 Oct 15. pii: 10.1038/s41409-018-0363.
    PubMed    


    August 2018
  75. PHILLIPS EH, Lannon MM, Lopes A, Chadwick H, et al
    High-dose chemotherapy and autologous stem cell transplantation in enteropathy-associated and other aggressive T-cell lymphomas: a UK NCRI/Cancer Research UK Phase II Study.
    Bone Marrow Transplant. 2018 Aug 13. pii: 10.1038/s41409-018-0294.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Malignant Lymphoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: